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Comparison of Major Adverse Cardiac Events
Between Instantaneous Wave-Free Ratio
and Fractional Flow Reserve–Guided Strategy
in Patients With or Without Type 2 Diabetes
A Secondary Analysis of a Randomized Clinical Trial
DEFINE-FLAIR Trial Investigators
IMPORTANCE Invasive physiologic indices such as fractional flow reserve (FFR) and
instantaneous wave-free ratio (iFR) are used in clinical practice. Nevertheless, comparative
prognostic outcomes of iFR-guided and FFR-guided treatment in patients with type 2
diabetes have not yet been fully investigated.
OBJECTIVE To compare 1-year clinical outcomes of iFR-guided or FFR-guided treatment in
patients with and without diabetes in the Functional Lesion Assessment of Intermediate
Stenosis to Guide Revascularization (DEFINE-FLAIR) trial.
DESIGN, SETTING, AND PARTICIPANTS The DEFINE-FLAIR trial is a multicenter, international,
randomized, double-blinded trial that randomly assigned 2492 patients in a 1:1 ratio to undergo
either iFR-guided or FFR-guided coronary revascularization. Patients were eligible for trial
inclusion if they had intermediate coronary artery disease (40%-70% diameter stenosis) in at
least 1 native coronary artery. Data were analyzed between January 2014 and December 2015.
INTERVENTIONS According to the study protocol, iFR of 0.89 or less and FFR of 0.80 or less
were used as criteria for revascularization. When iFR or FFR was higher than the prespecified
threshold, revascularization was deferred.
MAIN OUTCOMES AND MEASURES The primary end point was major adverse cardiac events
(MACE), defined as the composite of all-cause death, nonfatal myocardial infarction, or
unplanned revascularization at 1 year. The incidence of MACE was compared according to the
presence of diabetes in iFR-guided and FFR-guided groups.
RESULTS Among the total trial population (2492 patients), 758 patients (30.4%) had diabetes.
Mean age of the patients was 66 years, 76% were men (1868 of 2465), and 80% of patients
presented with stable angina (1983 of 2465). In the nondiabetes population (68.5%; 1707
patients), iFR guidance was associated with a significantly higher rate of deferral of
revascularization than the FFR-guided group (56.5% [n = 477 of 844] vs 46.6% [n = 402
of 863]; P < .001). However, it was not different between the 2 groups in the diabetes population
(42.1% [n = 161 of 382] vs 47.1% [n = 177 of 376]; P = .15). At 1 year, the diabetes population
showed a significantly higher rate of MACE than the nondiabetes population (8.6% vs 5.6%;
adjusted hazard ratio [HR], 1.88; 95% CI, 1.28-2.64; P < .001). However, there was no significant
difference in MACE rates between iFR-guided and FFR-guided groups in both the diabetes
(10.0% vs 7.2%; adjusted HR, 1.33; 95% CI, 0.78-2.25; P = .30) and nondiabetes population
(4.7% vs 6.4%; HR, 0.83; 95% CI, 0.51-1.35; P = .45) (interaction P = .25).
CONCLUSIONS AND RELEVANCE The diabetes population showed significantly higher risk of
MACE than the nondiabetes population, even with the iFR-guided or FFR-guided treatment.
The iFR-guided and FFR-guided treatment showed comparable risk of MACE and provided
equal safety in selecting revascularization target among patients with diabetes.
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T he presence of myocardial ischemia is the prerequisitefor the benefit of percutaneous coronary intervention(PCI).1,2 Fractional flow reserve (FFR) has been re-
garded as a standard invasive method to evaluate the func-
tional significance of epicardial coronary artery stenosis.3,4 In
2012, instantaneous wave-free ratio (iFR), a resting physi-
ologic index that does not require hyperemia, was intro-
duced and is also used in clinical practice. Two large-scale ran-
domized clinical trials showed noninferiority of iFR-guided
strategy compared with FFR-guided strategy in terms of 1-year
clinical outcomes.5,6
Type 2 diabetes is the third most common comorbidity
in patients with cardiovascular disease undergoing PCI
for ischemic heart disease.7 Even after successful PCI using
current-generation drug-eluting stents, diabetes is still an
independent predictor of major adverse events.8 Further-
more, previous studies showed that impaired endothelial
function, microvascular dysfunction, and depressed coro-
nary flow reserve occur even before the development of
significant epicardial coronary stenosis in patients with
diabetes.9-11 Therefore, resting and hyperemic pressure–
derived physiologic indices might perform differently and
have different prognostic implication in patients with diabe-
tes. In this regard, this study compared the clinical outcomes
of iFR-guided and FFR-guided strategy in patients with and
without diabetes.
Methods
Study Design and Patient Population
This study was a post hoc analysis of the Functional Lesion
Assessment of Intermediate Stenosis to Guide Revascularisa-
tion (DEFINE-FLAIR) trial, which was a multicenter, interna-
tional, randomized, double-blinded trial that explored non-
inferiority of iFR-guided strategy for 1-year clinical outcomes
compared with FFR-guided strategy.6 The study protocol
and main results were published previously.6 Patients were
eligible for trial inclusion if they had intermediate coronary
artery disease (40%-70% diameter stenosis on visual assess-
ment) in at least 1 native coronary artery. Patients with sig-
nificant left main stenosis (>50%), tandem stenoses sepa-
rated by more than 10 mm that would require separate
pressure guide wire interrogation or PCI, chronic total occlu-
sions, restenotic lesions, hemodynamic instability at the
time of PCI, heavily calcified or tortuous vessels, within 48
hours of primary PCI for ST-segment elevation myocardial
infarction, acute coronary syndrome with more than 1 target
vessel, previous coronary artery bypass graft surgery
(CABG), significant hepatic or lung disease and/or malignant
disease, severe valvular heart disease, and contraindication
to adenosine administration were excluded. For this study,
27 patients with unknown diabetes status were additionally
excluded from the total study population (N = 2492), result-
ing in 2465 patients being eligible for the analysis (Figure 1).
The study protocol was approved by the institutional review
board or ethics committee at each participating center, and
all patients provided written informed consent.
Procedure
After randomization into either the iFR-guided or FFR-
guided groups, physiologic measurements were obtained in
a routine manner with the use of a coronary-pressure guide
wire (Verrata; Philips Volcano). Before iFR or FFR measure-
ment, intracoronary nitrate was administered to control va-
somotor tone. After iFR or FFR measurement, according to
allocation group, prespecified treatment thresholds of iFR
(≤0.89) or FFR (≤0.80) were used as revascularization thresh-
old. When iFR or FFR for a given stenosis was equal to or lower
than the prespecified threshold, the stenosis was revascular-
ized using a drug-eluting stent or a bioresorbable vascular scaf-
fold or by CABG. When iFR or FFR was higher than the pre-
specified threshold, revascularization was deferred. For
patients allocated into the FFR-guided group, hyperemia was
induced by intravenous or intracoronary adenosine or other
agents. When PCI was attempted, revascularization was per-
formed in accordance with standard clinical practice, with
pharmacologic therapy left to the discretion of the treating
physician.
Study End Points
The primary end point of the trial was the 1-year risk of major
adverse cardiac events (MACE), which were a composite of
death, nonfatal myocardial infarction (MI), or unplanned re-
vascularization. Death was considered to be from cardiovas-
cular causes unless an unequivocal noncardiovascular cause
was established. Myocardial infarction was classified as either
spontaneous or periprocedural. Revascularization was con-
sidered to be unplanned when it was not the index procedure
and was not identified at the time of the index procedure as a
staged procedure to occur within 60 days. Detailed end point
definitions were previously published.6 End point events were
independently adjudicated by a committee of international ex-
perts who were not part of the steering committee and were
unaware of patient identity and their group assignment.
Statistical Analysis
Categorical variables were presented as numbers and relative
frequencies (percentages), and continuous variables were
Key Points
Question What are the comparative prognostic outcomes of
instantaneous wave-free ratio (iFR) vs fractional flow reserve
(FFR)–guided treatment in patients with type 2 diabetes?
Findings In this substudy of the DEFINE-FLAIR randomized
clinical trial, 1-year clinical outcomes of iFR-guided and FFR-guided
treatment were compared in patients with and without diabetes.
At 1 year, there was no significant difference in major adverse
cardiac event rates between iFR-guided and FFR-guided groups
in both populations with and without diabetes without significant
interaction.
Meaning In treatment of patients with diabetes with coronary
artery disease, iFR-guided and FFR-guided treatment showed
comparable risk of major adverse cardiac events and provided
equal safety in selecting revascularization target among patients
with diabetes.
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presented as means and standard deviations or median with
interquartile range (quartile 1 to quartile 3) according to their
distribution. The time-to-event analysis was conducted with
the use of the Kaplan-Meier method, and Cox proportional haz-
ards regression models were used to calculate hazard ratio
(HR) and 95% confidence interval. The validity of the propor-
tional hazards assumption was tested with Schoenfeld residu-
als, and Cox proportional hazard models for all clinical out-
comes satisfied the proportional hazards assumption. Data of
patients who withdrew from the study before 1 year follow-up
was reached and who were event-free at their last visit were
censored at the time of withdrawal for the time-to-event
analysis.6 As a primary analysis, multivariable adjusted analy-
sis with incorporation of covariates was performed. The co-
variates with clinical relevance or a univariate association with
outcome (P < .10) were entered into multivariable Cox mod-
els. Variables selected for inclusion were carefully chosen, given
the number of events available, to ensure parsimony of the
final models. The included covariates were age, sex, clinical
presentation, CCS class for grading of angina pectoris, hyper-
tension, hyperlipidemia, previous MI, and previous PCI. All
probability values were 2-sided, and P values less than .05 were
considered statistically significant.
Results
Characteristics of Patients and Lesions
Between Populations With and Without Diabetes
eTables 1 and 2 in the Supplement show clinical and procedural
characteristics of the trial population according to the presence
of diabetes. Mean age of the patients was 66 years, 76% were men
(1868 of 2465), and 80% of patients presented with stable angina
(1983 of 2465). Among the total population, 758 patients (30.4%)
had diabetes, 1707 patients (68.5%) did not, and 27 patients with
unknown diabetes status were excluded from the analysis
(Figure 1). Among the 758 patients with diabetes, 188 patients
(24.8%) were insulin-dependent. Compared with the nondiabe-
tes population, patients with diabetes showed a higher preva-
lence of hypertension and hypercholesterolemia. Regarding pro-
cedural characteristics, patients with diabetes showed a higher
number of functionally significant lesions, resulting in a higher
proportion of revascularized patients than in the nondiabetes
population.
Characteristics of Patients and Lesions
Between iFR-Guided and FFR-Guided Strategy Groups
eTables 3 and 4 in the Supplement show clinical and procedural
characteristics between iFR-guided and FFR-guided strategy
groups according to the presence of diabetes. When clinical char-
acteristics were compared between the 2 groups, there were no
significant differences in both the nondiabetes and diabetes
populations (eTables 3 in the Supplement). Among the nondia-
betes population, the iFR-guided group showed a lower number
of functionally significant lesions per patient and a lower preva-
lence of patients with at least 1 functionally significant lesion,
resulting in a higher proportion of deferred patients than in the
FFR-guided group (56.5% [n = 477 of 844] vs 46.6% [n = 402 of
863]; P < .001). Conversely, there was no significant difference
in number of functionally significant lesions per patient, propor-
tion of patients with at least 1 functionally significant lesion, or
deferred patients between the 2 groups among the diabetes
population (42.1% [n = 161 of 382] vs 47.1% [n = 177 of 376];
P = .15) (eTable 4 in the Supplement).
Clinical Outcomes in Patients With and Without Diabetes
At 1 year, the diabetes population showed significantly higher
risk of MACE (8.6% vs 5.6%; adjusted HR, 1.84; 95% CI, 1.28-
2.64; P < .001), mainly driven by higher risk of nonfatal MI and
unplanned revascularization than the nondiabetes popula-
tion (eFigure 1 and eTable 5 in the Supplement). When strati-
fied according to the presence of diabetes, both iFR-guided
and FFR-guided groups showed comparable risk of MACE in
both the nondiabetes (adjusted HR, 0.83; 95% CI, 0.51-1.35;
Figure 1. Study Flow
2492 Underwent randomization into iFR-
or FFR-guided strategy 
2535 Patients were assessed for eligibility
43 Were excluded
39 Did not meet the inclusion criteria
4 Were unwilling to participate
27 Were excluded due to unknown
information about diabetes mellitus
1707 Patients without diabetes 758 Patients with diabetes
844 Patients were assessed
with iFR 
863 Patients were assessed
with FFR
382 Patients were assessed
with iFR 
376 Patients were assessed
with FFR
This study was a post hoc analysis of
the Functional Lesion Assessment of
Intermediate Stenosis to Guide
Revascularisation (DEFINE-FLAIR)
trial. From the total trial population
(2492 patients), 2465 patients
(98.9% of trial population)
were included for the analysis.
FFR indicates fractional flow reserve;
iFR, instantaneous wave-free ratio.
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P = .45) and diabetes populations (adjusted HR, 1.33; 95% CI,
0.78-2.25; P = .25) without significant interaction (Figure 2 and
Table 1). There was no significant interaction regarding risk
of death from any cause, cardiovascular death, and un-
planned revascularization between treatment strategy and the
presence of diabetes. Among the diabetes population, the
iFR-guided group showed a higher incidence of nonfatal MI
than the FFR-guided group (HR, 2.61; 95% CI, 0.99-6.87;
P = .05) with significant interaction (interaction P value = .04)
(eFigure 2 in the Supplement). However, the difference in the
risk of nonfatal MI between iFR and FFR was mainly ob-
served in revascularized patients (eTable 6 in the Supple-
ment). When nonfatal MI was separated into spontaneous or
periprocedural MI, the significant interaction was mainly
driven by a higher incidence of target vessel MI in the iFR group
than the FFR group among the diabetes population (interac-
tion P value of target vessel MI = .03). However, there was no
skewed distribution of non–target vessel MI or periproce-
dural MI between the 2 groups, regardless of the presence of
diabetes. These results were consistent in unadjusted analy-
sis (eTable 7 in the Supplement). In addition, when the risk of
MACE was compared between iFR-guided and FFR-guided
groups according to non–insulin-dependent or insulin-
dependent diabetes, there were no significant differences in
the risk of MACE between the 2 groups, regardless of insulin
dependency (non–insulin-dependent diabetes: adjusted HR,
1.00; 95% CI, 0.49-2.04; P > .99; insulin-dependent diabe-
tes: adjusted HR, 1.85; 95% CI, 0.77-4.40; P = .17).
Among the total population, revascularization was deferred
in 878 patients (51.5%) and 338 patients (44.6%) in patients with
and without diabetes, respectively. In the deferred diabetes
population, the risk of MACE was not statistically different be-
tween the iFR-guided and FFR-guided groups (6.8% vs 5.1%;
adjusted HR, 0.98; 95% CI, 0.38-2.55; P = .58), and the com-
parable risk of MACE between the 2 groups was also similar in
the deferred nondiabetes population (3.1% vs 4.5%; adjusted
HR, 0.83; 95% CI, 0.37-1.85; P = .64) without significant inter-
action (P = .58) (Figure 3 and Table 2). These results were con-
sistent in unadjusted analysis (eTable 8 in the Supplement).
Discussion
This study analyzed 1-year clinical outcomes after physi-
ologic indices-guided treatment, according to the presence of
diabetes, and the main findings were as follows. First, pa-
tients with diabetes showed an almost 2-fold higher risk of
MACE than the nondiabetes population after invasive physi-
ologic index-guided treatment. Second, although iFR guid-
ance resulted in more deferral of revascularization among the
nondiabetes population, iFR-guided and FFR-guided strate-
gies resulted in similar rates of deferral among the diabetes
population. Third, despite the difference in deferral rates be-
tween iFR-guided and FFR-guided groups in the diabetes and
nondiabetes populations, iFR-guided and FFR-guided groups
showed comparable risk of MACE, regardless of the presence
of diabetes.
It is well known that patients with diabetes undergoing PCI
have worse prognosis than patients without diabetes. In this
study, even with the meticulous use of ischemia-directed PCI,
patients with diabetes showed about a 2-fold higher risk of
MACE compared with the nondiabetes population, regard-
less of treatment strategy. The significantly higher risk of MACE
in the diabetes population was mainly driven by a higher in-
cidence of nonfatal MI and unplanned revascularization.
These results are in line with previous studies that evaluated
all-comers undergoing PCI using second-generation drug-
eluting stent and support the importance of secondary pre-
vention and meticulous management of comorbidities in pa-
tients with diabetes.8,12
In patients with diabetes, there has been concern for un-
derestimation of ischemia with FFR owing to the relatively
higher prevalence of endothelial dysfunction, depressed
hyperemic myocardial blood flow (MBF), and microvascular
dysfunction.9-11 In an earlier study using dipyridamole-
positron emission tomography, hyperemic MBF and myocar-
dial flow reserve were significantly lower in patients with dia-
betes, while there was no difference in resting MBF between
Figure 2. Comparison of Major Adverse Cardiac Events (MACE)
Between Instantaneous Wave-Free Ratio (iFR)–Guided and Fractional
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Adjusted HR, 0.83; 95% CI, 0.51-1.35; P = .45
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Adjusted HR, 1.33; 95% CI, 0.78-2.25; P = .30
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Kaplan-Meier curves are shown for the comparison of 1-year rates of MACE
between iFR-guided and FFR-guided strategy groups in the nondiabetes
population (A) or diabetes population (B). HR indicates hazard ratio.
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asymptomatic non–insulin-dependent patients with diabe-
tes and an age-matched healthy control group.9,10 Because the
absolute MBF is a major determinant of the transstenotic pres-
sure gradient,13 decreased hyperemic MBF theoretically causes
underestimation of stenosis severity using hyperemic pressure–
derived indices in patients with diabetes, even with a similar
degree of stenosis compared with patients without diabetes.
Nevertheless, the results from the previous studies support the
benefit of an FFR-guided strategy, even in patients with
diabetes.14-19 For the diagnostic performance of FFR using
thallium-201 single-photon emission computed tomography
as a reference test, the best cutoff value of FFR and its diag-
nostic performance were not different between patients with
and without diabetes.14 In another study evaluating FFR value
according to stenosis severity between patients with and with-
out diabetes, there was no significant difference in the FFR
value.16,17 In addition, 2 large-scale prospective registries that
evaluated the prognosis of patients undergoing FFR-guided
treatment, including more than 2000 patients with diabetes,
showed favorable outcomes for those patients.19,20
Because iFR is measured during a resting state without
hyperemia induction, it would be expected to be less affected
by microvascular dysfunction compared with a hyperemic
physiologic index, where blunting of adenosine-induced hy-
peremia could potentially reduce the sensitivity of FFR. Con-
sidering the previous study results, which showed the pres-
ence of diabetes was significantly associated with the
discordant results between iFR and FFR,21 those 2 indices might
have different prognostic implications in patients with diabe-
tes. However, to our knowledge, there has been no report that
focused on the prognostic role of an iFR-guided strategy in pa-
tients with diabetes.
In our study, the FFR-guided group showed a higher num-
ber of functionally significant lesions than in the iFR-guided
group among the nondiabetes population. This result is in line
with a study by Lee et al,13 which showed that FFR was more
sensitive to anatomical and hemodynamic stenosis severity
than iFR. However, there were no significant differences in the
number of functionally significant lesions, number of pa-
tients with at least 1 functionally significant lesion, and the pro-
portion of revascularized patients between the 2 groups among
the diabetes population. This was mainly owing to the rela-
tive increase in revascularization rate in the iFR group among
the diabetes population. This might be explained by higher dis-
ease severity or plaque burden throughout the target vessels
in patients with diabetes or by the other factors that might
cause underestimation of epicardial lesion severity by FFR,
such as diffuse atherosclerotic narrowing, concomitant mi-
crovascular disease, or blunted response to hyperemic stimuli
in the diabetes population. However, because this trial did not
systematically assess intravascular imaging studies, further
study is needed to clarify this issue. Nevertheless, consider-
ing the comparable risk of MACE between iFR-guided and
FFR-guided groups among the diabetes population, the dif-
ferent response of iFR and FFR for the severity of epicardial
coronary stenosis might have limited effect on patient prog-
nosis. In addition, these results support the clinical relevance
of both an iFR-guided and FFR-guided strategy, even in pa-
tients with diabetes.
It is interesting to note that there was significant interac-
tion in the risk of nonfatal MI according to the presence of
diabetes. This was caused by the opposite direction of HR
between the nondiabetes and diabetes populations, espe-
cially for nonfatal target vessel MI. However, this result
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Primary end point: MACEb 40 (4.7) 55 (6.4) 0.83 (0.51-1.35) .45 38 (10.0) 27 (7.2) 1.33 (0.78-2.25) .30 .25
Cardiac death, MI, or unplanned
revascularization
34 (4.0) 47 (5.5) 0.81 (0.47-1.38) .43 31 (8.1) 26 (6.9) 1.15 (0.66-2.01) .61 .44
Death
Any cause 12 (1.4) 10 (1.2) 1.09 (0.42-2.85) .86 10 (2.6) 3 (0.8) 2.60 (0.68-10.0) .16 .31
Cardiovascular causes 5 (0.6) 2 (0.2) 1.27 (0.20-7.96) .80 2 (0.5) 2 (0.5) 0.93 (0.13-6.75) .95 .79
Noncardiovascular causes 7 (0.8) 8 (0.9) 1.00 (0.32-3.14) >.99 8 (2.1) 1 (0.3) 6.39 (0.74-54.8) .09 .16
Nonfatal myocardial infarction 13 (1.5) 21 (2.4) 0.56 (0.21-1.54) .26 18 (4.7) 7 (1.9) 2.61 (0.99-6.87) .05 .04
Spontaneous MI
Target vessel MI 3 (0.4) 12 (1.4) 0.32 (0.09-1.17) .08 6 (1.6) 2 (0.5) 3.26
(0.64-16.53)
.15 .03
Non–target vessel MI 2 (0.2) 2 (0.2) NA NA 7 (1.8) 5 (1.3) 1.68 (0.46-6.07) .43 .21
Periprocedural MI 8 (1.0) 7 (0.8) 1.94 (0.07-54.81) .70 5 (1.3) 0 NA NA .38
Unplanned revascularization 22 (2.6) 38 (4.4) 0.78 (0.44-1.38) .40 24 (6.3) 24 (6.4) 1.11 (0.62-2.00) .72 .49
Abbreviations: CCS, Canadian Cardiovascular Society; FFR, fractional flow
reserve; HR, hazard ratio; iFR, instantaneous wave-free ratio; MACE, major
adverse cardiac event; MI, myocardial infarction; NA, not applicable;
PCI, percutaneous coronary intervention.
a The included covariates in the multivariable-adjusted model were age, sex,
clinical presentation, CCS class for grading of angina pectoris, hypertension,
hyperlipidemia, previous MI, and previous PCI.
b MACE was defined as a composite of death from any cause, nonfatal
myocardial infarction, or unplanned revascularization.
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should be interpreted with caution owing to limited number
of events and sample size. In addition, the incidence of
unplanned revascularization and cardiovascular death was
almost the same between the 2 guided strategy groups
among the diabetes population. Furthermore, the excess
risk of nonfatal MI in the iFR group among the diabetes
population was statistically borderline (adjusted HR, 2.61;
95% CI, 0.99-6.87; P = .05) and the difference was mainly
observed in revascularized patients. Because this study
was a post hoc analysis that was not designed to detect the
possible difference in risk of nonfatal MI between the 2
groups, larger data sets are needed for the confirmation of
this finding.
It should be noted that angiography-only guided PCI in
patients with diabetes with multivessel disease has failed
to show benefit vs CABG.22 However, evidence from the
Synergy Between PCI With Taxus and Cardiac Surgery II
(SYNTAX II) study23 implies that ischemia-directed PCI
might have similar clinical outcomes with CABG in patients
with multivessel disease and equipoise risk between PCI and
CABG. Because anatomic residual disease did not show
prognostic implications after ischemia-directed PCI,24
iFR-guided or FFR-guided treatment should be emphasized
more in patients with diabetes.
Limitations
This study has several limitations. First, this study was an
exploratory post hoc analysis of the DEFINE-FLAIR trial.
Therefore, this post hoc analysis was not powered enough to
detect the potential differences in the risk of clinical events
between iFR and FFR groups. However, this study evaluated
the largest number of patients with diabetes evaluated by
iFR. Second, detailed data on diabetes status and treatment
were not available. Third, because the DEFINE-FLAIR trial
adopted exclusive allocation into either the iFR-guided or
FFR-guided group, the incidence of discordance between
the 2 indices according to the presence of diabetes and its
Figure 3. Deferred Population Outcome Between Instantaneous
Wave-Free Ratio (iFR)–Guided and Fractional Flow Reserve
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Kaplan-Meier curves are shown for the comparison of 1-year major adverse
cardiac event (MACE), defined as a composite of death from any cause,
nonfatal myocardial infarction, or unplanned revascularization, rates of
deferred population between iFR and FFR-guided strategy groups in the
nondiabetes population (A) or diabetes population (B). HR indicates
hazard ratio.
















(95% CI) P Value
Primary end point: MACEb 15 (3.1) 18 (4.5) 0.83 (0.37-1.85) .64 11 (6.8) 9 (5.1) 0.98 (0.38-2.55) .97 .58
Cardiac death, MI, or unplanned
revascularization
12 (2.5) 15 (3.7) 0.77 (0.32-1.87) .56 9 (5.6) 8 (4.5) 1.03 (0.38-2.83) .95 .54
Death
Any cause 5 (1.1) 3 (0.8) 1.30 (0.20-8.39) .78 2 (1.2) 1 (0.6) NA NA .83
Cardiovascular causes 2 (0.4) 0 NA NA 0 0 NA NA NA
Noncardiovascular causes 3 (0.6) 3 (0.8) 0.87 (0.11-7.12) .90 2 (1.2) 1 (0.6) NA NA .86
Nonfatal myocardial infarction 0 7 (1.7) NA NA 4 (2.5) 2 (1.1) 2.63 (0.35-19.99) .35 NA
Spontaneous MI
Target vessel MI 0 5 (1.2) NA NA 2 (1.2) 1 (0.6) 1.66 (0.05-53.81) .78 NA
Non–target vessel MI 0 1 (0.3) NA NA 2 (1.2) 1 (0.6) 2.81 (0.15-51.65) .49 NA
Periprocedural MI 0 1 (0.3) NA NA 0 0 NA NA NA
Unplanned revascularization 10 (2.1) 14 (3.5) 0.71 (0.29-1.78) .47 9 (5.6) 8 (4.5) 1.02 (0.37-2.80) .97 .47
Abbreviations: FFR, fractional flow reserve; HR, hazard ratio; iFR, instantaneous
wave-free ratio; MACE, major adverse cardiac event; MI, myocardial infarction;
NA, not applicable; PCI, percutaneous coronary intervention.
a The included covariates in the multivariable-adjusted model were age, sex,
clinical presentation, CCS class for grading of angina pectoris, hypertension,
hyperlipidemia, previous MI, and previous PCI.
b MACE was defined as a composite of death from any cause, nonfatal
myocardial infarction, or unplanned revascularization.
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prognostic implications could not be evaluated. Fourth,
invasive physiologic indices for evaluation of microvascular
dysfunction were not available. Fifth, because total disease
burden or microvascular assessment was not systematically
performed in this study, mechanistic explanations for differ-
ence in deferral rates in patients with diabetes could not
be clearly explained. Therefore, the possibility of play-
of-chance findings from a post hoc analysis cannot be
completely excluded.
Conclusions
The diabetes population showed significantly higher
risk of MACE than the nondiabetes population, even
with iFR-guided or FFR-guided treatment strategy. The iFR-
guided and FFR-guided treatments showed comparable risk
of MACE and provided equal safety in selecting revasculariza-
tion target among patients with diabetes.
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